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LETTERS
Avian Leukosis 
Virus Subgroup J 
in Layer Chickens, 
China
To the Editor: In recent years, 
cases of avian leukosis virus subgroup 
J (ALV-J) infection and tumors in com-
mercial layer chickens and breeders of 
egg-type chickens have been emerg-
ing in the People’s Republic of China. 
ALV-J was ﬁ  rst isolated from meat-
type chickens with myeloid leukosis 
in 1988. Although egg-type chickens 
have been experimentally infected 
with ALV-J to induce tumors (1), ﬁ  eld 
cases of ALV-J infection and tumors 
in commercial layer chickens were not 
found worldwide until 2004 (2).
ALV-J has recently been found 
to have induced various tumors and 
caused production problems in com-
mercial layer ﬂ  ocks and local chicken 
breeds in China (2,3). Many ﬁ  eld cas-
es of ALV-J infection and tumors have 
occurred in 15- to 29-week-old egg-
type chickens in several provinces. Af-
fected ﬂ  ocks had dramatically reduced 
egg production and hemorrhage in the 
skin surrounding the phalanges and 
feather follicles. Some birds had gray-
white nodules in the liver, spleen, or 
kidneys, and liver and spleen were en-
larged up to several times their normal 
size. Morbidity rates for some ﬂ  ocks 
reached 60%, and mortality rates for 
some ﬂ  ocks were >20%. Clinical sam-
ples from livers, spleens, whole blood, 
and tumors were collected from chick-
ens in different provinces and sent for 
laboratory diagnosis. Results showed 
that the predominant virus in the sam-
ples was ALV-J. 
During 2007–2009, we conducted 
an epidemiologic investigation of ALV 
in layer ﬂ  ocks in China. All virus iso-
lation was performed in DF-1 cells. 
Brieﬂ   y, 233 clinical samples were 
collected from 44 layer ﬂ  ocks in dif-
ferent provinces and used to inoculate 
subconﬂ   uent cell cultures containing 
Dulbecco modiﬁ   ed essential medium 
supplemented with 10% (vol/vol) fetal 
bovine serum and antimicrobial drugs. 
After a 7–9 day incubation period, the 
cells were frozen and thawed 3×. A 
group-speciﬁ  c antigen-capture ELISA 
was used to identify ALV. After pro-
viral DNA was extracted directly from 
infected cell culture or tumors, PCR 
with strain-speciﬁ  c primers was used 
to detect ALV-A, ALV-B, or ALV-J (4).
Of these samples, 150 (64.4%) 
were ALV-J positive, 28 (12.1%) 
were ALV-A positive, and 8 (3.4%) 
were ALV-B positive. Phylogenetic 
analysis showed an 87.3%–98.2% 
aa sequence identity of env genes in 
all ALV isolates compared with the 
HPRS-103 strain (5). All isolates had 
complete repeated transmembrane de-
letion and partial direct repeat–1 dele-
tion but contained an intact E element. 
A mutation was found in the enhancer 
and promoter region of the U3 region 
in the 3′ long terminal repeat; this mu-
tation is not found in ALV-J isolated 
from broiler chickens (6).
The newly isolated ALV-J strain 
from layer chickens was used to ex-
amine the pathogenicity in 1-day-old 
White Leghorn speciﬁ  c pathogen–free 
chicks soon after hatching in sepa-
rate incubators and rooms in the ex-
perimental animal house facilities at 
Harbin Veterinary Research Institute, 
Harbin, China. The chicks were inoc-
ulated intraabdominally with a 1,000-
unit 50% tissue-culture infective dose 
of ALV-J propagated in the DF-1 cells. 
Blood samples were collected to check 
for viremia at 10 weeks of age. Exper-
imental birds were reared until 27–30 
weeks of age.
Prolonged viremia developed in 
15 (50%) of 30 chicks; hemangiomas 
developed in the skin surrounding pha-
langes and in the liver of 3 (10%); and 
myeloid leukosis, detected by gross or 
histologic examination, developed in 
10 (30.3%). A previous study showed 
that meat-type birds infected with 
ALV-J retained a high level of viremia 
over their lifetime (7) but that layer 
chickens cleared the infection within 
a few weeks. Our study demonstrated 
that ALV-J infection can cause disease 
in layer chickens and can induce tu-
mors and long-lasting viremia. For 
this reason, disease caused by ALV-J 
in layer chickens in China should be 
further investigated. 
Because ALV-J is vertically trans-
mitted from dam to progeny by the 
embryo, it represents a potential threat 
for humans who receive vaccines that 
are produced in chicken embryonic 
ﬁ  broblasts or embryonated eggs (e.g., 
yellow fever vaccine and measles and 
mumps vaccine) (8). An effective 
vaccine against ALV is not available. 
Eradication of ALV-J has been dif-
ﬁ   cult because of substantial genetic 
and antigenic variation among ALV-J 
isolates as well as high levels of verti-
cal and horizontal transmission (9,10). 
Therefore, effective prevention and 
elimination measures should be devel-
oped as soon as possible.
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Healthcare Worker 
Acceptance of 
Pandemic (H1N1) 
2009 Vaccination, 
Morocco
To the Editor: In Morocco, the 
ﬁ  rst case of pandemic (H1N1) 2009 
was diagnosed on June 12, 2009 (1). 
Because a main determinant of public 
immunization success is healthcare 
workers’ support and recommenda-
tions and because little is known about 
such with regard to pandemic (H1N1) 
2009 vaccination in Morocco, our aim 
was to document healthcare workers’ 
knowledge, attitudes, practices, and 
acceptance of pandemic (H1N1) 2009 
vaccination in Morocco.
From January 15 through Febru-
ary 28, 2010, a structured, self-admin-
istered, anonymous questionnaire was 
distributed to a convenience sample of 
1,332 healthcare workers in 5 public 
hospitals in Rabat, Morocco. Com-
pleted questionnaires were analyzed 
by using SPSS version 10.0 (SPSS, 
Chicago, IL, USA).  The 1,002 re-
sponses gave a response rate of 75% 
(≈17% of the entire staff of the Uni-
versity Hospital of Rabat). 
We found that the hospital staff 
had acquired basic knowledge about 
transmission and prevention of the pan-
demic (H1N1) 2009 virus. Responses 
indicated that 218 (22%) study partic-
ipants had accepted vaccination (i.e., 
had been vaccinated) against this vi-
rus. Markedly more healthcare work-
ers in Morocco were undervaccinated 
than were those in the United States; 
by mid-January 2010, estimated vac-
cination coverage among healthcare 
workers was 37.1% (2). Some evi-
dence indicates that willingness of 
healthcare workers to be vaccinated 
with the new vaccine is poor: 48.0% 
in Hong Kong Special Administrative 
Region, People’s Republic of China 
(3) and 22.3% in the United States (4). 
Vaccination coverage was signiﬁ  cant-
ly higher for those 20–30 years of age 
than for those in other age groups (p = 
0.001). The analysis by occupational 
category showed signiﬁ  cantly higher 
coverage for paramedical staff (26%) 
than for physicians and pharmacists 
(19%) (p<0.01). The main causes for 
this reluctance were fear of adverse ef-
fects, concerns about the new adjuvant 
used, the short duration of clinical tri-
als, and inﬂ  uence of the media.
The low acceptance rate of vac-
cination for pandemic (H1N1) 2009 
among healthcare workers in Morocco 
is alarming because they serve as an 
example for their patients and the pub-
lic. Vaccination is needed to keep the 
healthcare system operating at maxi-
mum capacity during a pandemic. 
The following factors appear to play 
a major role in acceptance: accessibil-
ity of the vaccine within the service; 
free vaccine; and a display explaining 
vaccination’s beneﬁ  ts, protective val-
ue, and risk for adverse effects (5,6). 
Policy makers could use our ﬁ  ndings 
to improve the vaccination strategy for 
healthcare workers in future vaccina-
tion campaigns.
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